ClinicalTrials.gg
Not yet recruitingNCT06286696OpticUSUpdated Oct 9, 2024

Optic Nerve Sheath Diameter in Hypertensive Emergency

An observational study in Hypertensive Emergency, Papilledema and Hypertension, sponsored by Leiden University Medical Center. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by Leiden University Medical Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
375
Ages
18 Years and older
Sex
All
01

Study summary

This prospective observational study investigates the potential of point-of-care ultrasonography of the optic nerve sheath diameter (ONSD) to rule out papilledema in patients with suspected hypertensive emergency. The primary focus is on assessing ONSD sensitivity in identifying papilledema (hypertensive retinopathy grade 4), while secondary endpoints include hypertensive retinopathy grade 3, hypertensive encephalopathy, and the need for intravenous rapid-acting medications to lower elevated blood pressure. This study aims to determine the diagnostic characteristics of this procedure for the diagnosis of hypertensive retinopathy, thus assessing its potential as a screening tool to rule out hypertensive retinopathy by the acute internal medicine doctor.

02

Conditions studied

  • Hypertensive Emergency
  • Papilledema
  • Hypertension
03

In context

Hypertensive Crisis

31 studies on the registry are indexed under Hypertensive Crisis; 9 are open to participants now.

This study's planned enrollment of 375 is close to the median of 361 across 10 observational studies indexed under Hypertensive Crisis.

Browse Hypertensive Crisis studies →

Lead sponsor

Leiden University Medical Center is the lead sponsor of 334 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients presenting to the emergency department with suspected hypertensive emergency.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years old
  • Any patient presenting to the emergency department (ED) with suspected hypertensive emergency i.e.: blood pressure of > 200 millimetres of mercury (mmHg) systolic and/or > 120 mmHg diastolic

Exclusion criteria

Exclusion Criteria:

  • Patients with preexisting optic nerve head changes such as glaucoma, pre-existing retinal artery/vein occlusions or any other condition that makes assessment of the fundi impossible.
  • Primary neurological cause of hypertension: ischemic cerebrovascular incident
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
375 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testOptic Nerve Sheath Diameter

    Point of care ultrasonography of the optic nerve sheath diameter

06

What researchers measure

Primary outcomes

  1. Papilledema

    Sensitivity of ONSD \> 5mm for diagnosis of papilledema

    Time frame: 2 years

Secondary outcomes

  1. Hypertensive retinopathy grade 3 & 4 combined

    Sensitivity/specificity of the ONSD for hypertensive retinopathy grade 3 \& 4 combined

    Time frame: 2 years

  2. Hypertensive encephalopathy

    Sensitivity/specificity of the ONSD for hypertensive encephalopathy

    Time frame: 2 years

  3. Rapid acting medications administered intravenously to lower the elevated blood pressure

    Sensitivity/specificity of the ONSD for the need for rapid acting medications administered intravenously to lower the elevated blood pressure

    Time frame: 2 years

  4. Presence of a bulging optic nerve disc and/or crescent sign found by ultrasonography of the optic nerve

    Diagnostic characteristics for the presence of a bulging optic nerve disc and/or crescent sign for above mentioned diagnoses (papilledema, hypertensive retinopathy grade 3\&4 combined, hypertensive encephalopathy, need for rapid acting intravenous medications to lower elevated bloodpressure).

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2024; primary completion for Nov 2026, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2024
First posted
Feb 29, 2024
StartEst.
Nov 1, 2024
Primary completionEst.
Nov 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06286696
Responsible party
Tessa Mulder (Principal Investigator, Leiden University Medical Center) — Principal investigator
First posted
Feb 29, 2024
Start date
Nov 1, 2024 (estimated)
Primary completion
Nov 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Oct 9, 2024

Study contacts

Tessa Mulder, MD
Contact
t.a.mulder@lumc.nl
+31 71 52 96151
Martijn Bauer, MD, PhD
Contact
m.p.bauer@lumc.nl
+31 71 52 62381
Tessa Mulder, MD
principal investigator · Leiden University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion